Senior Vice President, Global Medical Affairs and Advocacy, Enable Injections
Mehul Desai, PharmD, RPh, MBA, is senior vice president of global medical affairs and advocacy and a member of the executive team at Enable Injections Inc., a Cincinnati-based company advancing large-volume subcutaneous drug delivery through its enFuse® on-body injector. Coming from argenx, where he developed the infrastructure for hematology medical affairs, Desai joined Enable as its first medical affairs hire to build the function from the ground up. He now leads global medical strategy, evidence generation and scientific advocacy across more than a dozen programs with partners including Sanofi, Roche, Sobi and Biogen. Enable’s technology earned its first FDA approval in 2023 with pegcetacoplan and has since secured regulatory approvals and clearances across global markets. In 2026, it reached a milestone with U.S. and European approvals of subcutaneous isatuximab, the first anticancer treatment administered via an on-body injector. Sanofi quoted Desai in its 2025 announcement of the pivotal Phase 3 results behind that approval. A pharmacist by training, Desai has centered his work on dispelling the subcutaneous delivery myths that have hindered drug development. He also leads one of the field’s broadest efforts measuring preference for on-body injectors, capturing nurse, pharmacist, physician, payer and patient perspectives. Desai has authored more than 10 peer-reviewed publications and delivered dozens of poster and podium presentations alongside renowned KOLs on subcutaneous biologic delivery. He is a frequently invited speaker and moderator at industry meetings and summits. He previously served in medical affairs at argenx, Alexion, Mallinckrodt and Johnson & Johnson. He earned his doctor of pharmacy degree from Purdue University and an MBA from Mayes College of Healthcare Business and Policy.
Follow him on LinkedIn.